Tarsus Pharmaceuticals, Inc. TARS

US Pharmaceuticals

$70.84 ▲ +3.27% (+$2.24)

⬆️ Above Yest. High

Open $69.81

Prev Close $68.60

Day Range $67.45 – $71.20

52W Range $53.89 – $91.53

Market Cap $3.38B

Beta 0.42

EPS (TTM) $-15.18

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-10-16
Shares Out.	48,890,000
Website	tarsusrx.com ↗
Phone	13025310855
Employees	370
Revenue	$194.6M
Gross Profit	$180.7M
Net Income	-$668.3M
Free Cash Flow	$32.4M
Total Assets	$505.5M
Total Liabilities	$401.5M
Equity	$104.0M

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Tarsus Pharmaceuticals, Inc. is a publicly traded company under the ticker symbol TARS on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.